Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCAR-T 2022 | Advances in CAR-T therapy for lymphoma

In this discussion chaired by David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, Caron Jacobson, MD, MMSc, Dana Farber Cancer Institute, Boston, MA, and Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talk on moving CAR-T therapy earlier in the treatment algorithm of high-risk large B-cell lymphoma (LCBL), and share their thoughts on the follow-up data of studies evaluating CAR-T therapy in mantle cell lymphoma (MCL) and follicular lymphoma (FL). Based on the results of the TRANSFORM (NCT03575351) and ZUMA-7 (NCT03391466) studies, the experts debate which LBCL patients should be selected to receive CAR-T therapy or autologous transplantation in the second-line setting. Additionally, Dr Maloney, Dr Jacobson and Dr Nastoupil comment on encouraging data from the ZUMA-12 study (NCT03761056) which provides strong evidence for further testing CAR-T therapy in the frontline setting. Moving forward, the experts talk on the efficacy of brexucabtagene autoleucel (brexu-cel) in MCL, and also talk on the updated data from the ZUMA-5 study (NCT03105336) in patients with FL, discussing the possibility of administering this therapy in the outpatient setting and of approaching a cure. This interview took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.